Queqiao Brings Good Tidings, Monthly Health Insights | August 2025
Harbour BioMed
Antibody Drug Developer
Pleryon
Ophthalmic Disease Therapeutics Developer
Healthgen Biotech
Research and Product Developer of Plant-derived Recombinant Protein Expression Technology
Click to follow? | Focus on Global Biomedical Investment
Today is the Qixi Festival, with a brilliant starry sky and magpies forming a bridge for reunion, symbolizing all beautiful connections and mutual endeavors. In the vast galaxy of hard tech investment, the "mutual dedication" between Everfront Capital and its invested companies has also borne fruitful results.
Looking back at August, some of the biopharmaceutical companies invested in by Edge Capital performed outstandingly, achieving a series of breakthroughs in financing progress, clinical developments, and approval statuses.
It is worth mentioning that the twoInvested Enterprises3D Medicines and Cadence Biotech "Join Hands" to Collaborate, Advancing the Development of tLNP-Delivered in vivo CAR-T/NK Therapy, Adding a Touch of Romance and Breakthrough to This "Journey" in Biopharmaceuticals.
01
Progress of Portfolio Companies' IPOs and Financing
Harbour BioMed
· Harbour BioMed Completes HKD 517 Million Placement of H Shares
On August 29, Harbour BioMed completed a placement of shares on the Hong Kong Stock Exchange through Citibank. The placement price was HK$11.5 per share, with a total of 45,022,000 shares placed. The gross and net proceeds from the placement were HK$517.8 million and HK$511.7 million, respectively. The net proceeds will be used for the following purposes: (i) approximately 50% will be used for the research and development of innovative drug assets; (ii) approximately 40% will be used to advance clinical trials of existing pipeline drug assets; (iii) approximately 10% will be used for working capital and other general corporate purposes.
Harbour BioMed
· Harbour BioMed Completes HKD 517 Million Placement of H Shares
On August 29, Harbour BioMed completed a placement of shares on the Hong Kong Stock Exchange through Citibank. The placement price was HK$11.5 per share, with a total of 45,022,000 shares placed. The gross and net proceeds from the placement were HK$517.8 million and HK$511.7 million, respectively. The net proceeds will be used for the following purposes: (i) approximately 50% will be used for the research and development of innovative drug assets; (ii) approximately 40% will be used to advance clinical trials of existing pipeline drug assets; (iii) approximately 10% will be used for working capital and other general corporate purposes.
Harbour BioMed
· Harbour BioMed Completes HKD 517 Million Placement of H Shares
On August 29, Harbour BioMed completed a placement of shares on the Hong Kong Stock Exchange through Citibank. The placement price was HK$11.5 per share, with a total of 45,022,000 shares placed. The gross and net proceeds from the placement were HK$517.8 million and HK$511.7 million, respectively. The net proceeds will be used for the following purposes: (i) approximately 50% will be used for the research and development of innovative drug assets; (ii) approximately 40% will be used to advance clinical trials of existing pipeline drug assets; (iii) approximately 10% will be used for working capital and other general corporate purposes.
Pleryon
· Pleryon Completes Tens of Millions in Series A Financing
Recently, Pleryon has completed a multi-million-dollar Series A financing round, led by EF Capital, a leading life science investment institution. This funding will support Pleryon's development across multiple indications, including advancing its core pipelines P001X and P002 in osteoarthritis and dry eye disease clinical research. The company plans to initiate patient recruitment for overseas clinical trials in 2026.
Quanxin Biotech
· Completion of Approximately HKD 100 Million New H Share Placement
On August 25, Quanxin Biotech was pleased to announce that the company has completed the placement of 5 million shares to TruMed Health Innovation Fund LP at a placement price of HKD 20.0 per share, raising a total of approximately HKD 100 million.
02
Clinical and Commercial Dynamics of Invested Companies
Healthgen Biotech
· Aofumin® Officially Used for Patient Treatment
Since the first shipment of Aofumin® on August 19, the first prescription was issued by a doctor on August 23, marking its initial use in the clinical treatment of patients with cirrhosis-related hypoalbuminemia. This signifies that Aofumin® has officially entered the clinical application stage, bringing good news to more patients.
Healthgen Biotech
· Aofumin® Officially Used for Patient Treatment
Since the first shipment of Aofumin® on August 19, the first prescription was issued by a doctor on August 23, marking its initial use in the clinical treatment of patients with cirrhosis-related hypoalbuminemia. This signifies that Aofumin® has officially entered the clinical application stage, bringing good news to more patients.
Protgen
· Beijing Protgen Biotechnology Development Co., Ltd.'s Recombinant Human Serum Albumin Injection Phase III Study Achieves Key Progress
Recently, the recombinant human serum albumin injection independently developed by Beijing Protgen Biotechnology Development Co., Ltd. successfully met the primary efficacy endpoint and key secondary efficacy endpoints required by the National Medical Products Administration in the pivotal Phase III clinical trial for the indication of cirrhotic ascites. The application for drug marketing authorization has been fully initiated.
Kash Biotech
· Global CDMO Solutions Shine on the International Stage
Recently, the 77th American Association for Clinical ChemistryAnnual Meeting and Clinical Trial PhysicianThe Academic Exposition has successfully concluded in Chicago. Pleryon, with its brand-new supply chain solutions, andFully Automatic Flow CytometerNew-generation flow fluorescence luminescence reader, consumables, and other exhibits debut at ADLM. Instrument engineers demonstrate the sample testing process on-site, showcasing Kayshine's technical prowess and attracting international customers.
Harbour BioMed
· Harbour BioMed Attends the First Evercore China Biotech Summit
From August 19 to 21, the first Evercore China Biotech Summit was held in Pudong, Shanghai. As a globally leading clinical-stage biopharmaceutical company, Harbour BioMed utilized this international platform to showcase its cutting-edge technological advancements and latest research achievements in innovative antibody drug development. Dr. Jinsong Wang, the company's founder, chairman, and CEO, highlighted the advantages of the company’s proprietary Harbour Mice® fully human antibody technology platform and introduced several innovative pipelines currently in clinical stages.
· Announcement of 2025 Mid-Year Results: Significant Growth in Revenue and Net Profit, Continuous Release of Platform Value
As of June 30, 2025, Harbour BioMed's total revenue for the first half of the year reached approximately RMB 725 million (about USD 101 million), representing a year-on-year increase of 327%; net profit was approximately RMB 523 million (about USD 73 million), marking a year-on-year increase of 51 times; cash reserves were abundant, amounting to approximately RMB 2.291 billion (about USD 320 million), representing a 92% growth compared to the end of last year. The company’s strong performance during the reporting period fully demonstrates the success of its business model and its robust financial development.
HaploX
· HaploX Showcases Cutting-Edge Technology Solutions, Drawing Wide Attention from Experts
From August 21 to 24, the 30th Academic Conference of the Pathology Branch of the Chinese Medical Association and the 14th Pathology Annual Meeting grandly opened in Shanghai. At the conference, the HaploX booth showcased a strong brand identity with its professionally designed layout and systematic product information. The comprehensive one-stop tumor gene detection solution presented on-site, featuring core products such as the HapSeq-2000 gene sequencer and supporting kits, precisely met clinical and research needs, attracting many experts in the field to stop by for in-depth discussions.
· HaploGenes Presents G20 All-A Team "Running God" Genetic Testing
Recently, HaploGen specially launched a free "Runner 258 Gene Test" exclusive benefit for all Team A members participating in Gobi 20, using the power of technology to ensure a safe journey through the Gobi Desert.
· Awarded Authoritative Certification for Multiple Projects
The College of American Pathologists (CAP) released the proficiency testing assessment reports for 2025CAP-NGSHM-A, 2025CAP-MSI-A, and 2025CAP-CFDNA-A. Shenzhen HaploX Medical Laboratory and HAPLOX GENETECH (HONG KONG) LIMITED both passed the above assessment items with perfect scores.
The National Center for Clinical Laboratories (NCCL) of the National Health Commission of China announced the External Quality Assessment Report on Bioinformatics Analysis of High-Throughput Sequencing for Somatic Mutation in Solid Tumors for 2025 and the Proficiency Testing Evaluation Report on Epstein-Barr Virus Nucleic Acid Testing (2nd Round) for 2025. Shenzhen HaploX Medical Laboratory achieved full marks in both assessment projects, marking another comprehensive recognition by NCCL of HaploX's technical management capabilities.
Jingwei Shida
· Hubei Provincial Science and Technology Department Key R&D Project "Development and Application Research of Cholangiopancreatic Confocal Microimaging Probe" Successfully Concluded
On August 23, the concluding meeting for the key R&D project of the Hubei Provincial Department of Science and Technology, "Research and Development and Application of Confocal Microimaging Probe for Biliary and Pancreatic Ducts," was held in Luotian, Hubei. The project was jointly applied for by Jingwei Shida, Ezhou Central Hospital, and Huazhong University of Science and Technology Ezhou Institute of Industrial Technology. As a leading enterprise in China's cellular endoscopy industry, Jingwei Shida takes clinical needs as its responsibility. Together with Ezhou Central Hospital and Huazhong University of Science and Technology Ezhou Industrial Research Institute, it formed a cross-disciplinary R&D team to jointly advance the "Research and Development and Application of Confocal Microimaging Probe for Biliary and Pancreatic Ducts."
· The Key Special Project of the Ministry of Science and Technology's "14th Five-Year Plan" – Competition for Diagnosis of Training Cases in Confocal Microendoscopy Technology Officially Launched
Recently, the training course for the application demonstration of ultrasound and confocal microendoscopy technology, a "14th Five-Year Plan" project by the Ministry of Science and Technology, was hosted by the Department of Gastroenterology of Shanghai Changhai Hospital and the National Clinical Research Center for Digestive Diseases (Shanghai), and co-organized by Jingwei Shida and Weizhi Medicine. Since its inception, the systematic clinical technology training has effectively promoted the standardized application of confocal technology in areas such as early gastrointestinal cancer screening.
· Multiple Academic Conferences Held Concurrently, Experts Explore New Advances in CLE Technology Clinical Applications
On August 15, Jingwei Shida held a special satellite meeting at the main venue of the "2025 Annual Academic Conference on Digestive Endoscopy of the Shaanxi Medical Association," inviting Professor Yang Zhuo from the General Hospital of the Northern Theater Command to share expertise on "The Value of Confocal Microendoscopy in Biliary Diseases."
· Sign Strategic Cooperation Agreement with Yongliang Machinery
On August 9, Precision Vision Technology and Suzhou Yongliang Machinery Equipment Co., Ltd. officially signed a strategic cooperation agreement. Feng Yu, CEO of Precision Vision Technology, and Zhao Jie, Chairman of Yongliang Machinery, attended the signing ceremony.
Protgen
· Beijing Protgen Biotechnology Development Co., Ltd.'s Recombinant Human Serum Albumin Injection Phase III Study Achieves Key Progress
Recently, the recombinant human serum albumin injection independently developed by Beijing Protgen Biotechnology Development Co., Ltd. successfully met the primary efficacy endpoint and key secondary efficacy endpoints required by the National Medical Products Administration in the pivotal Phase III clinical trial for the indication of cirrhotic ascites. The application for drug marketing authorization has been fully initiated.
Kash Biotech
· Global CDMO Solutions Shine on the International Stage
Kash Biotech
· Global CDMO Solutions Shine on the International Stage
Recently, the 77th American Association for Clinical ChemistryAnnual Meeting and Clinical Trial PhysicianThe Academic Exposition has successfully concluded in Chicago. Pleryon, with its brand-new supply chain solutions, andFully Automatic Flow CytometerNew-generation flow fluorescence luminescence reader, consumables, and other exhibits debut at ADLM. Instrument engineers demonstrate the sample testing process on-site, showcasing Kayshine's technical prowess and attracting international customers.
Harbour BioMed
· Harbour BioMed Attends the First Evercore China Biotech Summit
From August 19 to 21, the first Evercore China Biotech Summit was held in Pudong, Shanghai. As a globally leading clinical-stage biopharmaceutical company, Harbour BioMed utilized this international platform to showcase its cutting-edge technological advancements and latest research achievements in innovative antibody drug development. Dr. Jinsong Wang, the company's founder, chairman, and CEO, highlighted the advantages of the company’s proprietary Harbour Mice® fully human antibody technology platform and introduced several innovative pipelines currently in clinical stages.
· Announcement of 2025 Mid-Year Results: Significant Growth in Revenue and Net Profit, Continuous Release of Platform Value
As of June 30, 2025, Harbour BioMed's total revenue for the first half of the year reached approximately RMB 725 million (about USD 101 million), representing a year-on-year increase of 327%; net profit was approximately RMB 523 million (about USD 73 million), marking a year-on-year increase of 51 times; cash reserves were abundant, amounting to approximately RMB 2.291 billion (about USD 320 million), representing a 92% growth compared to the end of last year. The company’s strong performance during the reporting period fully demonstrates the success of its business model and its robust financial development.
HaploX
· HaploX Showcases Cutting-Edge Technology Solutions, Drawing Wide Attention from Experts
From August 21 to 24, the 30th Academic Conference of the Pathology Branch of the Chinese Medical Association and the 14th Pathology Annual Meeting grandly opened in Shanghai. At the conference, the HaploX booth showcased a strong brand identity with its professionally designed layout and systematic product information. The comprehensive one-stop tumor gene detection solution presented on-site, featuring core products such as the HapSeq-2000 gene sequencer and supporting kits, precisely met clinical and research needs, attracting many experts in the field to stop by for in-depth discussions.
· HaploGenes Presents G20 All-A Team "Running God" Genetic Testing
Recently, HaploGen specially launched a free "Runner 258 Gene Test" exclusive benefit for all Team A members participating in Gobi 20, using the power of technology to ensure a safe journey through the Gobi Desert.
· Awarded Authoritative Certification for Multiple Projects
The College of American Pathologists (CAP) released the proficiency testing assessment reports for 2025CAP-NGSHM-A, 2025CAP-MSI-A, and 2025CAP-CFDNA-A. Shenzhen HaploX Medical Laboratory and HAPLOX GENETECH (HONG KONG) LIMITED both passed the above assessment items with perfect scores.
The National Center for Clinical Laboratories (NCCL) of the National Health Commission of China announced the External Quality Assessment Report on Bioinformatics Analysis of High-Throughput Sequencing for Somatic Mutation in Solid Tumors for 2025 and the Proficiency Testing Evaluation Report on Epstein-Barr Virus Nucleic Acid Testing (2nd Round) for 2025. Shenzhen HaploX Medical Laboratory achieved full marks in both assessment projects, marking another comprehensive recognition by NCCL of HaploX's technical management capabilities.
Jingwei Shida
· Hubei Provincial Science and Technology Department Key R&D Project "Development and Application Research of Cholangiopancreatic Confocal Microimaging Probe" Successfully Concluded
On August 23, the concluding meeting for the key R&D project of the Hubei Provincial Department of Science and Technology, "Research and Development and Application of Confocal Microimaging Probe for Biliary and Pancreatic Ducts," was held in Luotian, Hubei. The project was jointly applied for by Jingwei Shida, Ezhou Central Hospital, and Huazhong University of Science and Technology Ezhou Institute of Industrial Technology. As a leading enterprise in China's cellular endoscopy industry, Jingwei Shida takes clinical needs as its responsibility. Together with Ezhou Central Hospital and Huazhong University of Science and Technology Ezhou Industrial Research Institute, it formed a cross-disciplinary R&D team to jointly advance the "Research and Development and Application of Confocal Microimaging Probe for Biliary and Pancreatic Ducts."
· The Key Special Project of the Ministry of Science and Technology's "14th Five-Year Plan" – Competition for Diagnosis of Training Cases in Confocal Microendoscopy Technology Officially Launched
Recently, the training course for the application demonstration of ultrasound and confocal microendoscopy technology, a "14th Five-Year Plan" project by the Ministry of Science and Technology, was hosted by the Department of Gastroenterology of Shanghai Changhai Hospital and the National Clinical Research Center for Digestive Diseases (Shanghai), and co-organized by Jingwei Shida and Weizhi Medicine. Since its inception, the systematic clinical technology training has effectively promoted the standardized application of confocal technology in areas such as early gastrointestinal cancer screening.
· Multiple Academic Conferences Held Concurrently, Experts Explore New Advances in CLE Technology Clinical Applications
On August 15, Jingwei Shida held a special satellite meeting at the main venue of the "2025 Annual Academic Conference on Digestive Endoscopy of the Shaanxi Medical Association," inviting Professor Yang Zhuo from the General Hospital of the Northern Theater Command to share expertise on "The Value of Confocal Microendoscopy in Biliary Diseases."
· Sign Strategic Cooperation Agreement with Yongliang Machinery
On August 9, Precision Vision Technology and Suzhou Yongliang Machinery Equipment Co., Ltd. officially signed a strategic cooperation agreement. Feng Yu, CEO of Precision Vision Technology, and Zhao Jie, Chairman of Yongliang Machinery, attended the signing ceremony.
Harbour BioMed
· Harbour BioMed Attends the First Evercore China Biotech Summit
From August 19 to 21, the first Evercore China Biotech Summit was held in Pudong, Shanghai. As a globally leading clinical-stage biopharmaceutical company, Harbour BioMed utilized this international platform to showcase its cutting-edge technological advancements and latest research achievements in innovative antibody drug development. Dr. Jinsong Wang, the company's founder, chairman, and CEO, highlighted the advantages of the company’s proprietary Harbour Mice® fully human antibody technology platform and introduced several innovative pipelines currently in clinical stages.
· Announcement of 2025 Mid-Year Results: Significant Growth in Revenue and Net Profit, Continuous Release of Platform Value
As of June 30, 2025, Harbour BioMed's total revenue for the first half of the year reached approximately RMB 725 million (about USD 101 million), representing a year-on-year increase of 327%; net profit was approximately RMB 523 million (about USD 73 million), marking a year-on-year increase of 51 times; cash reserves were abundant, amounting to approximately RMB 2.291 billion (about USD 320 million), representing a 92% growth compared to the end of last year. The company’s strong performance during the reporting period fully demonstrates the success of its business model and its robust financial development.
Harbour BioMed
· Harbour BioMed Attends the First Evercore China Biotech Summit
From August 19 to 21, the first Evercore China Biotech Summit was held in Pudong, Shanghai. As a globally leading clinical-stage biopharmaceutical company, Harbour BioMed utilized this international platform to showcase its cutting-edge technological advancements and latest research achievements in innovative antibody drug development. Dr. Jinsong Wang, the company's founder, chairman, and CEO, highlighted the advantages of the company’s proprietary Harbour Mice® fully human antibody technology platform and introduced several innovative pipelines currently in clinical stages.
· Announcement of 2025 Mid-Year Results: Significant Growth in Revenue and Net Profit, Continuous Release of Platform Value
As of June 30, 2025, Harbour BioMed's total revenue for the first half of the year reached approximately RMB 725 million (about USD 101 million), representing a year-on-year increase of 327%; net profit was approximately RMB 523 million (about USD 73 million), marking a year-on-year increase of 51 times; cash reserves were abundant, amounting to approximately RMB 2.291 billion (about USD 320 million), representing a 92% growth compared to the end of last year. The company’s strong performance during the reporting period fully demonstrates the success of its business model and its robust financial development.
HaploX
· HaploX Showcases Cutting-Edge Technology Solutions, Drawing Wide Attention from Experts
From August 21 to 24, the 30th Academic Conference of the Pathology Branch of the Chinese Medical Association and the 14th Pathology Annual Meeting grandly opened in Shanghai. At the conference, the HaploX booth showcased a strong brand identity with its professionally designed layout and systematic product information. The comprehensive one-stop tumor gene detection solution presented on-site, featuring core products such as the HapSeq-2000 gene sequencer and supporting kits, precisely met clinical and research needs, attracting many experts in the field to stop by for in-depth discussions.
· HaploGenes Presents G20 All-A Team "Running God" Genetic Testing
Recently, HaploGen specially launched a free "Runner 258 Gene Test" exclusive benefit for all Team A members participating in Gobi 20, using the power of technology to ensure a safe journey through the Gobi Desert.
· Awarded Authoritative Certification for Multiple Projects
The College of American Pathologists (CAP) released the proficiency testing assessment reports for 2025CAP-NGSHM-A, 2025CAP-MSI-A, and 2025CAP-CFDNA-A. Shenzhen HaploX Medical Laboratory and HAPLOX GENETECH (HONG KONG) LIMITED both passed the above assessment items with perfect scores.
The National Center for Clinical Laboratories (NCCL) of the National Health Commission of China announced the External Quality Assessment Report on Bioinformatics Analysis of High-Throughput Sequencing for Somatic Mutation in Solid Tumors for 2025 and the Proficiency Testing Evaluation Report on Epstein-Barr Virus Nucleic Acid Testing (2nd Round) for 2025. Shenzhen HaploX Medical Laboratory achieved full marks in both assessment projects, marking another comprehensive recognition by NCCL of HaploX's technical management capabilities.
Jingwei Shida
· Hubei Provincial Science and Technology Department Key R&D Project "Development and Application Research of Cholangiopancreatic Confocal Microimaging Probe" Successfully Concluded
On August 23, the concluding meeting for the key R&D project of the Hubei Provincial Department of Science and Technology, "Research and Development and Application of Confocal Microimaging Probe for Biliary and Pancreatic Ducts," was held in Luotian, Hubei. The project was jointly applied for by Jingwei Shida, Ezhou Central Hospital, and Huazhong University of Science and Technology Ezhou Institute of Industrial Technology. As a leading enterprise in China's cellular endoscopy industry, Jingwei Shida takes clinical needs as its responsibility. Together with Ezhou Central Hospital and Huazhong University of Science and Technology Ezhou Industrial Research Institute, it formed a cross-disciplinary R&D team to jointly advance the "Research and Development and Application of Confocal Microimaging Probe for Biliary and Pancreatic Ducts."
· The Key Special Project of the Ministry of Science and Technology's "14th Five-Year Plan" – Competition for Diagnosis of Training Cases in Confocal Microendoscopy Technology Officially Launched
Recently, the training course for the application demonstration of ultrasound and confocal microendoscopy technology, a "14th Five-Year Plan" project by the Ministry of Science and Technology, was hosted by the Department of Gastroenterology of Shanghai Changhai Hospital and the National Clinical Research Center for Digestive Diseases (Shanghai), and co-organized by Jingwei Shida and Weizhi Medicine. Since its inception, the systematic clinical technology training has effectively promoted the standardized application of confocal technology in areas such as early gastrointestinal cancer screening.
· Multiple Academic Conferences Held Concurrently, Experts Explore New Advances in CLE Technology Clinical Applications
On August 15, Jingwei Shida held a special satellite meeting at the main venue of the "2025 Annual Academic Conference on Digestive Endoscopy of the Shaanxi Medical Association," inviting Professor Yang Zhuo from the General Hospital of the Northern Theater Command to share expertise on "The Value of Confocal Microendoscopy in Biliary Diseases."
· Sign Strategic Cooperation Agreement with Yongliang Machinery
On August 9, Precision Vision Technology and Suzhou Yongliang Machinery Equipment Co., Ltd. officially signed a strategic cooperation agreement. Feng Yu, CEO of Precision Vision Technology, and Zhao Jie, Chairman of Yongliang Machinery, attended the signing ceremony.
HaploX
· HaploX Showcases Cutting-Edge Technology Solutions, Drawing Wide Attention from Experts
From August 21 to 24, the 30th Academic Conference of the Pathology Branch of the Chinese Medical Association and the 14th Pathology Annual Meeting grandly opened in Shanghai. At the conference, the HaploX booth showcased a strong brand identity with its professionally designed layout and systematic product information. The comprehensive one-stop tumor gene detection solution presented on-site, featuring core products such as the HapSeq-2000 gene sequencer and supporting kits, precisely met clinical and research needs, attracting many experts in the field to stop by for in-depth discussions.
· HaploGenes Presents G20 All-A Team "Running God" Genetic Testing
Recently, HaploGen specially launched a free "Runner 258 Gene Test" exclusive benefit for all Team A members participating in Gobi 20, using the power of technology to ensure a safe journey through the Gobi Desert.
· Awarded Authoritative Certification for Multiple Projects
The College of American Pathologists (CAP) released the proficiency testing assessment reports for 2025CAP-NGSHM-A, 2025CAP-MSI-A, and 2025CAP-CFDNA-A. Shenzhen HaploX Medical Laboratory and HAPLOX GENETECH (HONG KONG) LIMITED both passed the above assessment items with perfect scores.
The National Center for Clinical Laboratories (NCCL) of the National Health Commission of China announced the External Quality Assessment Report on Bioinformatics Analysis of High-Throughput Sequencing for Somatic Mutation in Solid Tumors for 2025 and the Proficiency Testing Evaluation Report on Epstein-Barr Virus Nucleic Acid Testing (2nd Round) for 2025. Shenzhen HaploX Medical Laboratory achieved full marks in both assessment projects, marking another comprehensive recognition by NCCL of HaploX's technical management capabilities.
Jingwei Shida
· Hubei Provincial Science and Technology Department Key R&D Project "Development and Application Research of Cholangiopancreatic Confocal Microimaging Probe" Successfully Concluded
On August 23, the concluding meeting for the key R&D project of the Hubei Provincial Department of Science and Technology, "Research and Development and Application of Confocal Microimaging Probe for Biliary and Pancreatic Ducts," was held in Luotian, Hubei. The project was jointly applied for by Jingwei Shida, Ezhou Central Hospital, and Huazhong University of Science and Technology Ezhou Institute of Industrial Technology. As a leading enterprise in China's cellular endoscopy industry, Jingwei Shida takes clinical needs as its responsibility. Together with Ezhou Central Hospital and Huazhong University of Science and Technology Ezhou Industrial Research Institute, it formed a cross-disciplinary R&D team to jointly advance the "Research and Development and Application of Confocal Microimaging Probe for Biliary and Pancreatic Ducts."
· The Key Special Project of the Ministry of Science and Technology's "14th Five-Year Plan" – Competition for Diagnosis of Training Cases in Confocal Microendoscopy Technology Officially Launched
Recently, the training course for the application demonstration of ultrasound and confocal microendoscopy technology, a "14th Five-Year Plan" project by the Ministry of Science and Technology, was hosted by the Department of Gastroenterology of Shanghai Changhai Hospital and the National Clinical Research Center for Digestive Diseases (Shanghai), and co-organized by Jingwei Shida and Weizhi Medicine. Since its inception, the systematic clinical technology training has effectively promoted the standardized application of confocal technology in areas such as early gastrointestinal cancer screening.
· Multiple Academic Conferences Held Concurrently, Experts Explore New Advances in CLE Technology Clinical Applications
On August 15, Jingwei Shida held a special satellite meeting at the main venue of the "2025 Annual Academic Conference on Digestive Endoscopy of the Shaanxi Medical Association," inviting Professor Yang Zhuo from the General Hospital of the Northern Theater Command to share expertise on "The Value of Confocal Microendoscopy in Biliary Diseases."
· Sign Strategic Cooperation Agreement with Yongliang Machinery
On August 9, Precision Vision Technology and Suzhou Yongliang Machinery Equipment Co., Ltd. officially signed a strategic cooperation agreement. Feng Yu, CEO of Precision Vision Technology, and Zhao Jie, Chairman of Yongliang Machinery, attended the signing ceremony.
Jingwei Shida
· Hubei Provincial Science and Technology Department Key R&D Project "Development and Application Research of Cholangiopancreatic Confocal Microimaging Probe" Successfully Concluded
On August 23, the concluding meeting for the key R&D project of the Hubei Provincial Department of Science and Technology, "Research and Development and Application of Confocal Microimaging Probe for Biliary and Pancreatic Ducts," was held in Luotian, Hubei. The project was jointly applied for by Jingwei Shida, Ezhou Central Hospital, and Huazhong University of Science and Technology Ezhou Institute of Industrial Technology. As a leading enterprise in China's cellular endoscopy industry, Jingwei Shida takes clinical needs as its responsibility. Together with Ezhou Central Hospital and Huazhong University of Science and Technology Ezhou Industrial Research Institute, it formed a cross-disciplinary R&D team to jointly advance the "Research and Development and Application of Confocal Microimaging Probe for Biliary and Pancreatic Ducts."
· The Key Special Project of the Ministry of Science and Technology's "14th Five-Year Plan" – Competition for Diagnosis of Training Cases in Confocal Microendoscopy Technology Officially Launched
Recently, the training course for the application demonstration of ultrasound and confocal microendoscopy technology, a "14th Five-Year Plan" project by the Ministry of Science and Technology, was hosted by the Department of Gastroenterology of Shanghai Changhai Hospital and the National Clinical Research Center for Digestive Diseases (Shanghai), and co-organized by Jingwei Shida and Weizhi Medicine. Since its inception, the systematic clinical technology training has effectively promoted the standardized application of confocal technology in areas such as early gastrointestinal cancer screening.
· Multiple Academic Conferences Held Concurrently, Experts Explore New Advances in CLE Technology Clinical Applications
On August 15, Jingwei Shida held a special satellite meeting at the main venue of the "2025 Annual Academic Conference on Digestive Endoscopy of the Shaanxi Medical Association," inviting Professor Yang Zhuo from the General Hospital of the Northern Theater Command to share expertise on "The Value of Confocal Microendoscopy in Biliary Diseases."
· Sign Strategic Cooperation Agreement with Yongliang Machinery
On August 9, Precision Vision Technology and Suzhou Yongliang Machinery Equipment Co., Ltd. officially signed a strategic cooperation agreement. Feng Yu, CEO of Precision Vision Technology, and Zhao Jie, Chairman of Yongliang Machinery, attended the signing ceremony.
Bioinno Biotech
· Analysis and Testing Center Officially Passes CNAS Certification, Opening a New Chapter of High-Quality Development
Bioinno Biotech
· Analysis and Testing Center Officially Passes CNAS Certification, Opening a New Chapter of High-Quality Development
Recently, the Bioanalytical Testing Center of Bioinno Biotech has officially passed the CNAS certification. This is not only a milestone event in the company’s development history but also signifies that its professional capabilities in the field of biological testing have gained internationally recognized "credentials," injecting strong momentum into promoting industry standardization and technological innovation.
US-China Dual Harmony
· Golden Harvest-Zhongke Balloon Products of US-China Shuanghe Group Win Bidding in Centralized Procurement
US-China Dual Harmony
· Golden Harvest-Zhongke Balloon Products of US-China Shuanghe Group Win Bidding in Centralized Procurement
US-China Dual Harmony
· Golden Harvest-Zhongke Balloon Products of US-China Shuanghe Group Win Bidding in Centralized Procurement
Recently, the balloon products of Jinh禾中科 (a subsidiary of Meizhong Shuanghe Group) have won bids in the centralized procurement projects: [Beijing-Tianjin-Hebei “ㄋ+N” Alliance], [Guangdong Province Coronary Balloon Medical Consumables Alliance], and [Shanghai City Coronary Balloon Centralized Procurement]!
Tian Gang Medical
· First Patient Dosed in Phase I Clinical Trial of New Anti-Cancer Drug TGI-5
Tian Gang Medical
· First Patient Dosed in Phase I Clinical Trial of New Anti-Cancer Drug TGI-5
Tian Gang Medical
· First Patient Dosed in Phase I Clinical Trial of New Anti-Cancer Drug TGI-5
On August 6, Tian Gang Yi Nuo announced that the monoclonal antibody drug (Project Code: TGI-5), independently developed by the company, completed the first patient enrollment and dosing (FPI) in Phase I clinical trial at the Fudan University-affiliated Cancer Hospital.
Lingyi Biotech
· World's First! Zhejiang University First Affiliated Hospital Completes Gene Therapy for Adolescent Patients with Wilson's Disease
Lingyi Biotech
· World's First! Zhejiang University First Affiliated Hospital Completes Gene Therapy for Adolescent Patients with Wilson's Disease
Lingyi Biotech
· World's First! Zhejiang University First Affiliated Hospital Completes Gene Therapy for Adolescent Patients with Wilson's Disease
Recently, a clinical study titled "A Prospective, Single-Center, Open-Label, Single-Arm, Single-Dose Study to Evaluate the Safety, Tolerability, and Efficacy of LY-M003 Injection in Adult and Pediatric Patients with Wilson’s Disease" has been successfully conducted at the First Affiliated Hospital of Zhejiang University School of Medicine. The LY-M003 injection used in the clinical study was provided by Lingyi Bio.
Epicoding Biotech
· Dr. Yang Yun interviewed by Oriental Finance Pudong Channel on AI-powered circular RNA therapy
Epicoding Biotech
· Dr. Yang Yun interviewed by Oriental Finance Pudong Channel on AI-powered circular RNA therapy
Epicoding Biotech
· Dr. Yang Yun interviewed by Oriental Finance Pudong Channel on AI-powered circular RNA therapy
Recently, Dr. Yang Yun, co-founder, chairman, and CTO of Huanma Biotech, and Dr. Tang Chenxiang, CEO of Huanma Biotech, were interviewed by Oriental Finance reporters. They discussed accelerating the clinical application of "one-shot long-term repair" for coronary heart disease through AI-powered circular RNA therapy.
Ruijing Biotech
· Molecular Pathology of Thyroid Cancer Enters a New Era
Ruijing Biotech
· Molecular Pathology of Thyroid Cancer Enters a New Era
Ruijing Biotech
· Molecular Pathology of Thyroid Cancer Enters a New Era
Ruijing Biotech
· Molecular Pathology of Thyroid Cancer Enters a New Era
Recently, the 30th Academic Conference of the Chinese Society of Pathology and the 14th Annual Pathology Conference were grandly held at the Shanghai World Expo Center, gathering numerous experts to celebrate this grand event and write a brilliant chapter together. During the conference, Ruijing Biotech presented its heavyweight product — the only multi-gene joint detection kit specifically approved by NMPA for thyroid nodules: Human BRAF/TERT/CCDC6-RET Gene Mutation Detection Kit (Fluorescence PCR Method) (Registration Certificate No.: National Medical Device Approval 20233401165) — at this academic event, while simultaneously hosting the "Ruijian Precision" academic symposium.
Aomer Pharma
· Groundbreaking Ceremony of the Industrialization Base Successfully Held
On the morning of August 21, the groundbreaking ceremony for the Aomorph Pharmaceutical Industrial Base Project – Aogrape Pharmaceutical was grandly held in the Binhai New Area of Shaoxing City. Wang Kaifeng, partner of Edge Capital, attended the ceremony as a shareholder representative of Aomorph Pharmaceutical.
Aomer Pharma
· Groundbreaking Ceremony of the Industrialization Base Successfully Held
On the morning of August 21, the groundbreaking ceremony for the Aomorph Pharmaceutical Industrial Base Project – Aogrape Pharmaceutical was grandly held in the Binhai New Area of Shaoxing City. Wang Kaifeng, partner of Edge Capital, attended the ceremony as a shareholder representative of Aomorph Pharmaceutical.
Aomer Pharma
· Groundbreaking Ceremony of the Industrialization Base Successfully Held
On the morning of August 21, the groundbreaking ceremony for the Aomorph Pharmaceutical Industrial Base Project – Aogrape Pharmaceutical was grandly held in the Binhai New Area of Shaoxing City. Wang Kaifeng, partner of Edge Capital, attended the ceremony as a shareholder representative of Aomorph Pharmaceutical.
Noliv Biotech
· Nollet Biotech Showcases Nitric Oxide Therapy Technology at High-Altitude Pulmonary Hypertension Symposium
Noliv Biotech
· Nollet Biotech Showcases Nitric Oxide Therapy Technology at High-Altitude Pulmonary Hypertension Symposium
August 8-10, "AI Empowering Highland Health and Special Academic Seminar on Highland Pulmonary Hypertension" was grandly held in Lhasa. This conference, hosted by the Medical Association of the Tibet Autonomous Region, brought together top experts from home and abroad, including academicians Wu Tianyi, Wang Zhenchang, and Nyima Tashi, to jointly explore the innovative integration of AI technology and highland medicine. As a pioneer in the field of nitric oxide (NO) therapy, Novabio deeply participated in the conference, showcasing its technological breakthroughs and application prospects in the treatment of highland pulmonary hypertension.
Xuanyu Medical
· Multiple Hospitals First to Conduct XuanYu RhythPulse® PFA Surgeries
Xuanyu Medical
· Multiple Hospitals First to Conduct XuanYu RhythPulse® PFA Surgeries
Xuanyu Medical
· Multiple Hospitals First to Conduct XuanYu RhythPulse® PFA Surgeries
Recently, the cardiology team at Deyang People's Hospital successfully performed one of the first nationwide and the first RhythPulse® Pulsed Field Ablation (PFA) surgeries in Sichuan Province using the Xuan Yu Medical RhythPulse® system.
Prof. Wang Hao from the team of President Hua Junyi and Director Hu Pengfei of the Second Affiliated Hospital of Zhejiang Chinese Medical University successfully performed atrial fibrillation pulsed field ablation surgery on a patient with atrial fibrillation using the RhythPulse® pulsed field ablation catheter developed by Xuan Yu Medical.
The Department of Cardiology at the Tenth People's Hospital Affiliated to Tongji University successfully applied the domestically produced RhythPulse®-PFA Pulse Ablation System to perform pulse ablation treatment on a patient with paroxysmal atrial fibrillation.
The team led by Director Lu Qi from the Affiliated Hospital of Nantong University successfully completed one of the first batch of RhythPulse®-PFA Pulse Electric Field Ablation surgeries in China, utilizing the domestically produced XuanYu Medical RhythPulse®-PFA system.
Qianxinan People's Hospital Successfully Applies China-Made RhythPulse® Under the Leadership of Director Chen Jiulin-PFA Pulse Ablation System was used to perform atrial fibrillation pulse ablation on three patients with atrial fibrillation.
The arrhythmia team of the Department of Cardiovascular Medicine at Shanghai Chest Hospital applied the domestically produced Xuan Yu RhythPulse-PFA pulse ablation system to perform minimally invasive pulsed electric field ablation treatment on two patients with paroxysmal atrial fibrillation.
Affiliated to Qingdao UniversityRizhao Hospital / Rizhao Heart Disease Hospital Cardiology Second Diagnostic Team Successfully Utilizes XuanYu Medical RhythPulse® Pulsed Field Ablation Catheter to Perform Pulsed Field Ablation Surgery for a Patient with Atrial Fibrillation.
The Cardiology Department of Shanghai Seventh People's Hospital, in collaboration with the Anesthesiology Department and the medical team, successfully applied RhythPulse by XuanYu Medical.®Pulsed Field Ablation Catheter Performs Pulsed Field Ablation for Two Patients with Atrial Fibrillation.
· Multiple FieldsLearning Activity Successfully Concluded
The "Pulsed Electric Field Ablation New Technology Workshop" hosted by Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine was held on the 4th floor of the inpatient department at the Fengxian Campus of Xinhua Hospital. The conference was a complete success.
The "New Technology Training Course for Pulse Ablation in the Treatment of Atrial Fibrillation," hosted by the Oriental Huaxia Cardiovascular Health Research Institute of Suzhou Industrial Park, successfully took place in Shanghai on August 1, 2025. Xuan Yu Medical participated as a strategic supporter of the conference, presenting a thematic training session titled "Comprehensive and Targeted Ablation."
"Shanghai Chest Hospital Pulmonary Vein Isolation and Left Atrial Appendage Occlusion Training Course," hosted by Shanghai Oasis of Life Public Welfare Service Center, organized by Shanghai Chest Hospital, and strategically supported by Xuanyu Medical, was held in the Shanfang Hall of Shanghai Chest Hospital.
The Cardiology Department of Shanghai Seventh People's Hospital, in collaboration with the Anesthesiology Department and the medical team, successfully applied RhythPulse by XuanYu Medical.®Pulsed Field Ablation Catheter Performs Pulsed Field Ablation for Two Patients with Atrial Fibrillation.
· Multiple FieldsLearning Activity Successfully Concluded
The "Pulsed Electric Field Ablation New Technology Workshop" hosted by Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine was held on the 4th floor of the inpatient department at the Fengxian Campus of Xinhua Hospital. The conference was a complete success.
The "New Technology Training Course for Pulse Ablation in the Treatment of Atrial Fibrillation," hosted by the Oriental Huaxia Cardiovascular Health Research Institute of Suzhou Industrial Park, successfully took place in Shanghai on August 1, 2025. Xuan Yu Medical participated as a strategic supporter of the conference, presenting a thematic training session titled "Comprehensive and Targeted Ablation."
"Shanghai Chest Hospital Pulmonary Vein Isolation and Left Atrial Appendage Occlusion Training Course," hosted by Shanghai Oasis of Life Public Welfare Service Center, organized by Shanghai Chest Hospital, and strategically supported by Xuanyu Medical, was held in the Shanfang Hall of Shanghai Chest Hospital.
· Multiple FieldsLearning Activity Successfully Concluded
The "Pulsed Electric Field Ablation New Technology Workshop" hosted by Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine was held on the 4th floor of the inpatient department at the Fengxian Campus of Xinhua Hospital. The conference was a complete success.
The "New Technology Training Course for Pulse Ablation in the Treatment of Atrial Fibrillation," hosted by the Oriental Huaxia Cardiovascular Health Research Institute of Suzhou Industrial Park, successfully took place in Shanghai on August 1, 2025. Xuan Yu Medical participated as a strategic supporter of the conference, presenting a thematic training session titled "Comprehensive and Targeted Ablation."
"Shanghai Chest Hospital Pulmonary Vein Isolation and Left Atrial Appendage Occlusion Training Course," hosted by Shanghai Oasis of Life Public Welfare Service Center, organized by Shanghai Chest Hospital, and strategically supported by Xuanyu Medical, was held in the Shanfang Hall of Shanghai Chest Hospital.
Century Kangle
· First Case in Xuzhou, Among the First Batch in China
On the morning of August 6, Xuzhou Aier Eye Hospital successfully performed cataract phacoemulsification surgery on a mother and implanted the "Liang Shi An® New Generation Trifocal Plus" intraocular lens, which is the first of its kind in Xuzhou and among the first batch in China.
Century Kangle
· First Case in Xuzhou, Among the First Batch in China
On the morning of August 6, Xuzhou Aier Eye Hospital successfully performed cataract phacoemulsification surgery on a mother and implanted the "Liang Shi An® New Generation Trifocal Plus" intraocular lens, which is the first of its kind in Xuzhou and among the first batch in China.
Weimai Medical
· WeMed Innovation Brings the World's First "Eye-Hand-Brain" Intervention Solution to Latin America, Chinese High-End Medical Equipment Shines in Mexico
Recently, Weimai Medical Technology appeared at the Expo Med Hospitalar Mexico 2025 exhibition in Mexico. At this exhibition, Weimai Medical Technology highlighted its revolutionary "Eye-Hand-Brain" coordinated interventional solution, especially its core product—the We RobotDSA·Interventional Robot—demonstrating China's leading position in the field of high-end interventional medical equipment technology.
· ChinaChina's Innovative Stage "Highlight Moment"! Interventional Robots Set New Heights in Hardcore Technology
Recently, the Beijing Innovative Medical Device Matchmaking and Medical Robot Scenario Exhibition was grandly held in Beijing.WeMed脱颖而出，携介入机器人受邀参展，相关负责人现场发表主题演讲，以硬核技术实力诠释中国医疗机器人领域的"国家担当"。
· China-Hospeq 2025: Heavyweight Launch of Interventional Robots
From August 15 to 17, the 31st China International Medical Equipment Exhibition and Technical Exchange Conference was grandly held at the Beijing National Convention Center. Relevant national health departments, local health commissions, embassies in China, international organizations, more than a hundred hospital directors, and industry representatives attended the conference to discuss the development of global health.Weimai Medical Technology Unveils Fully Self-Developed Interventional Robot at Medical Innovation Exhibition, Announcing to the World that China's Intelligent Manufacturing is Reshaping the New Healthcare Ecosystem.
· CEO and CTO Speak on the Same Stage, Jointly Outlining the "China Solution" for Cardiovascular Interventions
Recently, the Innomedcon Beijing Innovation Forum 2025 was successfully held in Beijing. As a representative of technological innovation in the field of interventional diagnosis and treatment, Weimai Medical's CEO He Yang and CTO Jing Xie deeply participated in the "Innovation and Development of Cardiovascular Interventional Devices" sub-forum. Through keynote speeches and roundtable dialogues, they conveyed to the industry the evolutionary path of interventional robots, as well as strategic thoughts on the iteration of cardiovascular interventional technology and industrial upgrading.
· Debuting at CCME2025 with Cutting-Edge Technology
Recently, Nanjing Yangtze River International Conference Center has become the focus of global medical technology attention - "Global Medical Device Innovation Conference and the 9th Endoscopy Conference (CCME2025")" was grandly held in this fervent atmosphere. At this top event, which gathered 3,500 industry elites and covered multiple international markets, Weimai Medical attended with its cutting-edge technology, was invited to the Surgical Robotics Conference and Minimally Invasive Surgery Seminar (Full-scenario Application of Surgical Robots), and delivered a keynote speech titled "Reshaping Interventions: The Future of Weimai Medical's Interventional Surgical Robots."
Kaituo Biotech
· And3D Medicines Partners to Advance tLNP Delivery for in vivo CAR-T/NK Therapy Development
On August 20, in Shanghai, China, 3D Medicines and Cadon Biotech officially signed a strategic cooperation agreement. According to the agreement, the two parties will collaborate based on 3D Medicines' self-developed AI+mRNA R&D platform with proprietary intellectual property rights and lipid delivery system (3D-LNP), along with Cadon Biotech’s mRNA technology.Leverage the advantages and experience of large-scale production to deepen cooperation in areas such as targeted LNP delivery (tLNP), tumor vaccines, and in vivo CAR-T/NK.
· Release2025 Mid-Year Performance Review
In the first half of 2025, Kaituozhe delivered a solid performance in response to trust, presenting an interim report card that stands up to scrutiny. The number of new orders was nearly 200, with order value increasing by 155% year-on-year. Sales revenue grew by 233% year-on-year. Overseas orders accounted for 30% of total order value and 35% of total revenue. The total number of cooperative clients exceeded 300, with nearly 50 new additions, and 50% of clients made repeat purchases.
· Release2025 Mid-Year Performance Review
In the first half of 2025, Kaituozhe delivered a solid performance in response to trust, presenting an interim report card that stands up to scrutiny. The number of new orders was nearly 200, with order value increasing by 155% year-on-year. Sales revenue grew by 233% year-on-year. Overseas orders accounted for 30% of total order value and 35% of total revenue. The total number of cooperative clients exceeded 300, with nearly 50 new additions, and 50% of clients made repeat purchases.
· Release2025 Mid-Year Performance Review
In the first half of 2025, Kaituozhe delivered a solid performance in response to trust, presenting an interim report card that stands up to scrutiny. The number of new orders was nearly 200, with order value increasing by 155% year-on-year. Sales revenue grew by 233% year-on-year. Overseas orders accounted for 30% of total order value and 35% of total revenue. The total number of cooperative clients exceeded 300, with nearly 50 new additions, and 50% of clients made repeat purchases.
3D Medicines
· Collaborate with Kaituo Biotech to Advance the Development of tLNP-Delivered in vivo CAR-T/NK Therapy
On August 20, in Shanghai, China, 3D Medicines and Cadon Biotech officially signed a strategic cooperation agreement.
· Independently Developed New Generation of Precision Nuclear Medicine Administered to First Patient
On August 28, 3D Medicines officially announced that the first patient dosing has been completed in the IIT study of 177Lu-PSMA-3D1015 Injection, the first radiopharmaceutical conjugate (RDC) developed by the company's self-developed nuclear medicine platform.
Quanxin Biotech
· ESG Rating Upgraded to A Level: Sustainable Development Capability Receives Authoritative Certification
Recently, the authoritative financial data institution Wind released its latest ESG rating. Quanxin Biotech achieved a leap in ESG rating from BBB to A due to its efforts in ESG governance, advancing into the forefront of industry leaders in sustainable development.
Quanxin Biotech
Quanxin Biotech
· ESG Rating Upgraded to A Level: Sustainable Development Capability Receives Authoritative Certification
Recently, the authoritative financial data institution Wind released its latest ESG rating. Quanxin Biotech achieved a leap in ESG rating from BBB to A due to its efforts in ESG governance, advancing into the forefront of industry leaders in sustainable development.
· QY Biotech 2025 Mid-Year Earnings Release Q&A
August 19，Quanxin BiotechHeld the Mid-term Results Briefing for 2025. At the meeting, Chairman of the Board and General Manager Mr. Qiu Jiwan, Vice General Manager Mr. Lin Weidong, and Board Secretary Mr. Hu Yanbao jointly shared the company's outstanding achievements in the first half of 2025 and responded to the hot issues of concern to investors.
· Phase III +1!QX004N / HS-20137 Enters Phase III Clinical Trial for Psoriasis (Ps)
Recently, QX004N / HS-20137, co-developed by Quanxin Biotech and Hansoh Pharma, has entered the Phase III clinical trial stage for psoriasis (Psoriasis, Ps), becoming the fourth product in Quanxin Biotech's pipeline to successfully advance to Phase III clinical trials.
Ascentage Pharma
· Ascentage Pharma Announces 2025 First-Half Financial Results, Strong Sales Growth of 93% for Naxitamab®
Ascentage Pharma
· Ascentage Pharma Announces 2025 First-Half Financial Results, Strong Sales Growth of 93% for Naxitamab®
Ascentage Pharma
· Ascentage Pharma Announces 2025 First-Half Financial Results, Strong Sales Growth of 93% for Naxitamab®
Recently, Ascentage Pharma announced its financial results for the first half of 2025. The product sales revenue of Nulasta® (Olverembatinib) increased by 93% year-on-year to RMB 217 million, mainly due to the expanded coverage of the drug in the National Medical Insurance Catalog.
Pulmonary Technology
· Launch of "Sandwich Method" Estradiol (E2) Ushers in a New Era of Small Molecule Detection!
Recently, Promedtech released the "Sandwich Method" Estradiol (E2), overcoming the three major technical bottlenecks of traditional estradiol detection: significantly improving anti-interference performance, achieving high-sensitivity detection of low-concentration samples (<20 pg/mL), and showing high consistency with the LC-MS/MS method.
Pulmonary Technology
· Launch of "Sandwich Method" Estradiol (E2) Ushers in a New Era of Small Molecule Detection!
Recently, Promedtech released the "Sandwich Method" Estradiol (E2), overcoming the three major technical bottlenecks of traditional estradiol detection: significantly improving anti-interference performance, achieving high-sensitivity detection of low-concentration samples (<20 pg/mL), and showing high consistency with the LC-MS/MS method.
· Promed Technology 2025 Semi-Annual Report
Recently, ProMed Tech released its semi-annual report for 2025. In the first half of the year, the company reported operating revenue of 507 million yuan, net profit attributable to shareholders of 122 million yuan, non-recurring net profit attributable to shareholders of 111 million yuan, earnings per share of 0.28 yuan/share, and net operating cash flow of 117 million yuan.
Asieris Pharmaceuticals
· Potential FIC! APL-1401, developed by Asieris Pharmaceuticals for the treatment of moderate to severe active ulcerative colitis, achieves positive preliminary results in Phase Ib clinical trial
8Month1On [date], Asieris Pharmaceuticals announced that its oral medicationAPL-1401Treatment of Moderate to Severe Active Ulcerative Colitis - IbPhase clinical trial obtained positive preliminary results.
· Update on the Progress of APL-1702 Marketing Application
Recently, Asia-Pacific Pharmaceutical announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has initiated the second round of technical review for APL-1702, a photodynamic drug-device combination product for the non-surgical treatment of cervical high-grade squamous intraepithelial lesion (HSIL). The company's team will maintain active communication with the CDE in the hope of completing the new drug marketing evaluation process as soon as possible.
· Chief Business Officer Ms. Xu Ying Attended the Breast Cancer Diagnosis and Treatment Expert Forum and Delivered a Speech
Recently, the "Building a Strong Foundation · Celebrating New Life with 'Ou'" Breast Cancer Diagnosis and Treatment Expert Forum, hosted by the Beijing Association for Chronic Disease Prevention and Health Education, was successfully held in Beijing. Ms. Xu Ying, Chief Commercial Officer of Yaron Pharmaceuticals, attended and delivered a speech: "We will fully leverage our commercialization advantages and expert resources in the field of oncology to accelerate the nationwide application of Onarlin®, fulfilling our commitment to provide innovative solutions for patients."
· Asia Pharma Releases 2025 Interim Report
Recently, AsiaPharm released its semi-annual report for 2025, with operating revenue reaching 130 million yuan, a year-on-year increase of 61.8%, achieving the business target for the first half of the year. Two breakthrough innovative products are ready to launch: APL-1702’s debut in China is entering the final sprint stage, and Hexvix® ushers in a new era of blue light diagnosis and treatment for bladder cancer. The company has a cash reserve of approximately 1.825 billion yuan, providing a solid foundation for steady growth.
· Promed Technology 2025 Semi-Annual Report
Recently, ProMed Tech released its semi-annual report for 2025. In the first half of the year, the company reported operating revenue of 507 million yuan, net profit attributable to shareholders of 122 million yuan, non-recurring net profit attributable to shareholders of 111 million yuan, earnings per share of 0.28 yuan/share, and net operating cash flow of 117 million yuan.
Asieris Pharmaceuticals
· Potential FIC! APL-1401, developed by Asieris Pharmaceuticals for the treatment of moderate to severe active ulcerative colitis, achieves positive preliminary results in Phase Ib clinical trial
8Month1On [date], Asieris Pharmaceuticals announced that its oral medicationAPL-1401Treatment of Moderate to Severe Active Ulcerative Colitis - IbPhase clinical trial obtained positive preliminary results.
· Update on the Progress of APL-1702 Marketing Application
Recently, Asia-Pacific Pharmaceutical announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has initiated the second round of technical review for APL-1702, a photodynamic drug-device combination product for the non-surgical treatment of cervical high-grade squamous intraepithelial lesion (HSIL). The company's team will maintain active communication with the CDE in the hope of completing the new drug marketing evaluation process as soon as possible.
· Chief Business Officer Ms. Xu Ying Attended the Breast Cancer Diagnosis and Treatment Expert Forum and Delivered a Speech
Recently, the "Building a Strong Foundation · Celebrating New Life with 'Ou'" Breast Cancer Diagnosis and Treatment Expert Forum, hosted by the Beijing Association for Chronic Disease Prevention and Health Education, was successfully held in Beijing. Ms. Xu Ying, Chief Commercial Officer of Yaron Pharmaceuticals, attended and delivered a speech: "We will fully leverage our commercialization advantages and expert resources in the field of oncology to accelerate the nationwide application of Onarlin®, fulfilling our commitment to provide innovative solutions for patients."
· Asia Pharma Releases 2025 Interim Report
Recently, AsiaPharm released its semi-annual report for 2025, with operating revenue reaching 130 million yuan, a year-on-year increase of 61.8%, achieving the business target for the first half of the year. Two breakthrough innovative products are ready to launch: APL-1702’s debut in China is entering the final sprint stage, and Hexvix® ushers in a new era of blue light diagnosis and treatment for bladder cancer. The company has a cash reserve of approximately 1.825 billion yuan, providing a solid foundation for steady growth.
Asieris Pharmaceuticals
· Potential FIC! APL-1401, developed by Asieris Pharmaceuticals for the treatment of moderate to severe active ulcerative colitis, achieves positive preliminary results in Phase Ib clinical trial
8Month1On [date], Asieris Pharmaceuticals announced that its oral medicationAPL-1401Treatment of Moderate to Severe Active Ulcerative Colitis - IbPhase clinical trial obtained positive preliminary results.
· Update on the Progress of APL-1702 Marketing Application
Recently, Asia-Pacific Pharmaceutical announced that the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) has initiated the second round of technical review for APL-1702, a photodynamic drug-device combination product for the non-surgical treatment of cervical high-grade squamous intraepithelial lesion (HSIL). The company's team will maintain active communication with the CDE in the hope of completing the new drug marketing evaluation process as soon as possible.
· Chief Business Officer Ms. Xu Ying Attended the Breast Cancer Diagnosis and Treatment Expert Forum and Delivered a Speech
Recently, the "Building a Strong Foundation · Celebrating New Life with 'Ou'" Breast Cancer Diagnosis and Treatment Expert Forum, hosted by the Beijing Association for Chronic Disease Prevention and Health Education, was successfully held in Beijing. Ms. Xu Ying, Chief Commercial Officer of Yaron Pharmaceuticals, attended and delivered a speech: "We will fully leverage our commercialization advantages and expert resources in the field of oncology to accelerate the nationwide application of Onarlin®, fulfilling our commitment to provide innovative solutions for patients."
· Asia Pharma Releases 2025 Interim Report
Recently, AsiaPharm released its semi-annual report for 2025, with operating revenue reaching 130 million yuan, a year-on-year increase of 61.8%, achieving the business target for the first half of the year. Two breakthrough innovative products are ready to launch: APL-1702’s debut in China is entering the final sprint stage, and Hexvix® ushers in a new era of blue light diagnosis and treatment for bladder cancer. The company has a cash reserve of approximately 1.825 billion yuan, providing a solid foundation for steady growth.
MicroCore Biotech
· Top Journal in Hepatology! Results of Phase II Trial on Siglitazone Sodium (DualoPing) Monotherapy for MASH Published in "Hepatology"
MicroCore Biotech
· Top Journal in Hepatology! Results of Phase II Trial on Siglitazone Sodium (DualoPing) Monotherapy for MASH Published in "Hepatology"
Recently, the Phase II clinical research results of Chiglitazar Sodium (DualoPad®), a type 2 diabetes drug independently developed by Chipscreen Biosciences for the treatment of metabolic associated fatty liver disease, were published in the top international journal *Hepatology* in the field of hepatology. The study showed that after 18 weeks of treatment with Chiglitazar Sodium, patients' liver fat content decreased by 40%, and over 70% of patients' liver enzymes returned to normal range.
· MicroCore Biotech 2025 Innovation Summit Successfully Concludes: AI + Core Technology Integrated Platform Boosts Original New Drug Development
On August 18, the 2025 Chipscreen Biosciences Innovation Seminar Summit was successfully held in Shanghai. The summit provided an in-depth interpretation of the application of the company’s “AI-assisted design + chemogenomics integrated technology platform” in new drug development, comprehensively showcased its extensive clinical layout both in China and internationally, and presented in detail the next-generation global First-in-Class early-stage R&D pipeline developed based on the AI-integrated platform.
03
Approval Status of New Drugs and Devices from Invested Companies
Healthgen Biotech
· "Plant-derived recombinant human albumin" approved for Phase III clinical trials in the United States
Recently, Healthgen Biotech announced that its self-developed Class I therapeutic biological product, recombinant human albumin injection (rice) (brand name: Aofumin), has completed a Type C meeting with the U.S. FDA regarding the "Global Multicenter Clinical Study Design." Both parties have reached a consensus on the Phase III clinical study protocol for the international multicenter trial.
· Assisting Chengdu Yusai Nuowei's UC101 Project in Obtaining IND Approval in China
8Month22Day,Healthgen Biotech provided Chengdu Usino Biotech Co., Ltd. with a highly efficient recombinant protein expression platform through a rice endosperm cell bioreactor (OryzHiExp) produced animal-free, high-purity, and stably supplied plant-derived recombinant human serum albumin (Recombinant Human Serum Albumin, OsrHSA), contributing to the successful approval of its project's IND application in both China and the United States.
Innolab Medical
· Breakthrough in China! The First Ultrasound Electronic Bronchoscope System Officially Approved for Marketing
Recently, the first ultrasound electronic bronchoscope system by YINGMEIDA has been officially approved for marketing, defining a new era in pulmonary diagnosis and treatment, and assisting clinical precision puncture for efficient diagnosis and treatment.
Innolab Medical
· Breakthrough in China! The First Ultrasound Electronic Bronchoscope System Officially Approved for Marketing
Recently, the first ultrasound electronic bronchoscope system by YINGMEIDA has been officially approved for marketing, defining a new era in pulmonary diagnosis and treatment, and assisting clinical precision puncture for efficient diagnosis and treatment.
Kaituo Biotech
· BoostQT-019B from Qihan Bio Receives FDA Clinical Trial Approval
On August 13, Qihan Bio announced that the Investigational New Drug (IND) application for its first self-developed universal dual-target CAR-T cell product, QT-019B, has been officially approved by the U.S. Food and Drug Administration (FDA). In this milestone project, CatiBio undertook the core gene-editing mRNA preparation task, delivering high-standard outputs that meet international clinical submission requirements.
Century Kaitai
· Meishi Season® Orthokeratology Lens Glorious Launch
Recently, Century Kangtai's AI-optimized algorithm orthokeratology lens, Meishi Season®, has been gloriously launched.
Ascentage Pharma
· The global Phase III clinical trial of Risantol® for the first-line treatment of intermediate- and high-risk MDS patients has been approved by the U.S. FDA and European EMA.
Recently, Ascentage Pharma announced that the global pivotal Phase III clinical trial (GLORA-4) of its self-developed Bcl-2 selective inhibitor lisaftoclax (brand name: Rishengtuo®; research code: APG-2575) in combination with azacitidine (AZA) for the treatment of newly diagnosed high-risk myelodysplastic syndromes (HR-MDS) has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Century Kaitai
· Meishi Season® Orthokeratology Lens Glorious Launch
Recently, Century Kangtai's AI-optimized algorithm orthokeratology lens, Meishi Season®, has been gloriously launched.
Ascentage Pharma
· The global Phase III clinical trial of Risantol® for the first-line treatment of intermediate- and high-risk MDS patients has been approved by the U.S. FDA and European EMA.
Recently, Ascentage Pharma announced that the global pivotal Phase III clinical trial (GLORA-4) of its self-developed Bcl-2 selective inhibitor lisaftoclax (brand name: Rishengtuo®; research code: APG-2575) in combination with azacitidine (AZA) for the treatment of newly diagnosed high-risk myelodysplastic syndromes (HR-MDS) has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Century Kaitai
· Meishi Season® Orthokeratology Lens Glorious Launch
Recently, Century Kangtai's AI-optimized algorithm orthokeratology lens, Meishi Season®, has been gloriously launched.
Century Kaitai
· Meishi Season® Orthokeratology Lens Glorious Launch
Century Kaitai
· Meishi Season® Orthokeratology Lens Glorious Launch
Century Kaitai
· Meishi Season® Orthokeratology Lens Glorious Launch
Recently, Century Kangtai's AI-optimized algorithm orthokeratology lens, Meishi Season®, has been gloriously launched.
Ascentage Pharma
· The global Phase III clinical trial of Risantol® for the first-line treatment of intermediate- and high-risk MDS patients has been approved by the U.S. FDA and European EMA.
Recently, Ascentage Pharma announced that the global pivotal Phase III clinical trial (GLORA-4) of its self-developed Bcl-2 selective inhibitor lisaftoclax (brand name: Rishengtuo®; research code: APG-2575) in combination with azacitidine (AZA) for the treatment of newly diagnosed high-risk myelodysplastic syndromes (HR-MDS) has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Ascentage Pharma
· The global Phase III clinical trial of Risantol® for the first-line treatment of intermediate- and high-risk MDS patients has been approved by the U.S. FDA and European EMA.
Recently, Ascentage Pharma announced that the global pivotal Phase III clinical trial (GLORA-4) of its self-developed Bcl-2 selective inhibitor lisaftoclax (brand name: Rishengtuo®; research code: APG-2575) in combination with azacitidine (AZA) for the treatment of newly diagnosed high-risk myelodysplastic syndromes (HR-MDS) has been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Frontier Biotech
· Successfully Obtained "Double Certificates" for Medical Devices
Frontier Biotech
· Successfully Obtained "Double Certificates" for Medical Devices
Recently, the far-infrared treatment patch developed by the company successfully obtained the Medical Device Production License (Certificate No.: Lu Drug Supervision Medical Device Production Permit 20250076) and the Medical Device Registration Certificate (Lu Medical Device Approval No. 20252090416) issued by the Shandong Provincial Drug Administration. The simultaneous approval of these two core qualifications is a double affirmation of the company's R&D strength and compliance management system.
NorthX Biotech
· NorthX Smart Digital Pressure Pump iFlowX™ Approved for Marketing
NorthX Biotech
· NorthX Smart Digital Pressure Pump iFlowX™ Approved for Marketing
On August 5, Beixins iFlowX™ Digital Pressure Pump officially received the Class II Medical Device Registration Certificate from the Guangdong Provincial Drug Administration. As the first digital pressure pump system with intelligent functions, it enhances surgical convenience and precision through three key technologies, advancing basic consumables into a "digital and intelligent" new era.
Xuanzhu Biotech
· Xuanzhu Biotech's ALK Inhibitor Derokac Approved for Marketing
On August 22, the official website of the National Medical Products Administration (NMPA) announced that Diroac tablets (Product code: XZP-3621), a Class 1 innovative anti-tumor drug independently developed by Xuanzhu Biotech, a non-wholly owned subsidiary of Four Rings Medicine Group, had been approved for marketing. The drug is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who are positive for anaplastic lymphoma kinase (ALK) and have not been previously treated with an ALK inhibitor.
04
Honors of Invested Enterprises
Selected as Haoyue [Best Innovative Medical Device Company of the Year]
· Core Medical, Nollet Biotech, Immdx
Selected as Haoyue [Best Innovative Pharmaceutical Company of the Year]
· Pleryon, Westlake Biotech
Selected for PharmaCircle and CMC-CHINA China Pharmaceutical Industry Expo [Top 101 Innovative Chinese Pharmaceutical Companies 2025]
· Ascentage Pharma, Chipscreen Biosciences, Harbour BioMed, Frontier Biotech, Asieris Pharmaceuticals, Prokon Biotech, Genuine Biotech, Quanxin Biotech, Enmu Biotech, Xuanzhu Biotech
Selected for the Health Triumph and Health Triumph Research Institute [Top 100 Innovative Medical Devices in China's Healthcare Growth Sector 2025]
· Weimai Medical
Selected for the Galien Foundation's [2025 Galien Award "Best Startup" Candidate List]
· Harbour BioMed Subsidiary Nona Biosciences
Selected for the Ministry of Industry and Information Technology of China's [List of Landmark Biomanufacturing Products 2024 (First Batch)]
· Healthgen BiotechObjectAofumin®
SelectedSecond Prize in the Enterprise Group of the 10th "Maker China" and "Zhejiang Good Projects" SME Innovation and Entrepreneurship Competition, Hangzhou Region Finals
· AND017 First-in-Class Pan-Anemia Therapy Hemoglobin Enhancer (HbEA) by AnDao Pharmaceuticals
Selected as one of the 40 Under 40 Business Elites in China by Fortune China 2025
· Bai Xiaosong, Founder and General Manager of ImVision Medical
Selected for ESMO 2025 Poster Presentation
· HaploX MRD Research Achievements
Selected as one of the 40 Under 40 Business Elites in China by Fortune China 2025
· Bai Xiaosong, Founder and General Manager of ImVision Medical
Selected for ESMO 2025 Poster Presentation
· HaploX MRD Research Achievements
Selected for ESMO 2025 Poster Presentation
· HaploX MRD Research Achievements
05
Yifeng Honor
06
Yifeng Article Sharing for This Month
✦
Recommended Reading
✦
Bokang Vision Cloud Hong Kong Main Board IPO
Healthgen Biotech Hong Kong Main Board IPO
Quanxin Biotech Hong Kong Main Board IPO
Against the Current, Moving Forward with Time
3D Medicines Hong Kong Main Board IPO
Healthgen Biotech STAR Market IPO
A Decade of Sharpening the Sword - When Drawn, It Must Shine
AsiaPharm's STAR Market IPO
Looking forward to your
Share
Like
In Progress
✦
Recommended Reading
✦
Bokang Vision Cloud Hong Kong Main Board IPO
Bokang Vision Cloud Hong Kong Main Board IPO
Healthgen Biotech Hong Kong Main Board IPO
Quanxin Biotech Hong Kong Main Board IPO
Against the Current, Moving Forward with Time
3D Medicines Hong Kong Main Board IPO
Healthgen Biotech STAR Market IPO
A Decade of Sharpening the Sword - When Drawn, It Must Shine
AsiaPharm's STAR Market IPO
Looking forward to your
Share
Like
In Progress